Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic mesenchymal stem cells (IIS-Puerta de Hierro)
- Development stage
- Unknown
- Lead developer
- Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Inhalation
01
Overview
Allogeneic mesenchymal stem cells (MSCs) developed by the Instituto De Investigación Sanitaria Puerta De Hierro-Segovia De Arana are an investigational cell therapy designed to treat chronic lung allograft dysfunction (CLAD). CLAD, which includes bronchiolitis obliterans syndrome (BOS), is a major complication following lung transplantation characterized by chronic inflammation and progressive airway fibrosis. These MSCs are administered endobronchially to deliver the cells directly to the affected lung tissue. The therapeutic rationale is based on the potent immunomodulatory and anti-inflammatory properties of MSCs, which can suppress the aberrant immune responses driving graft rejection and promote a pro-regenerative environment to stabilize lung function.
- Other names
- Allogeneic mesenchymal stromal cellsMSCsMesenchymal stem cells
Beyond the preview
Go deeper on allogeneic mesenchymal stem cells (IIS-Puerta de Hierro).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic mesenchymal stem cells (IIS-Puerta de Hierro).